Message from the Guest Editor

Dear Colleagues,

There is currently significant interest in the discovery and development of epigenetic drugs for many chronic diseases, including cancer, inflammatory, metabolic and neuro-psychiatric conditions. It is hypothesised that these may modify the transcription of many causative genes implicated in the development and maintenance of such diseases, and hence inhibitors of these proteins may deliver novel disease modifying therapeutics. There are questions, however, around the tolerability or therapeutic index of such agents. In this issue we will discuss the latest developments in both academia and industry.

Prof. Dr. Chas Bountra
Guest Editor
Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High visibility:** citations available in PubMed, full-text archived in PubMed Central. Covered by Embase and Scopus. To be indexed in the Emerging Sources Citation Index - ESCI (Web of Science) from Vol. 10 (2017).

**CiteScore** (2018 Scopus data): 3.80, which equals rank 23/164 (Q1) in 'Pharmaceutical Science' and rank 39/165 (Q1) in 'Molecular Medicine'.

Contact Us

*Pharmaceuticals*

MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com